List of Figures
Figure 1: Biopharmaceutical Manufacturing, Number of FDA Approved Biopharmaceuticals, the US, 1982-2011
Figure 2: Biopharmaceutical Manufacturing, Percentage Share of Biopharmaceuticals in the Global Pharmaceutical Market, 2001-2011
Figure 3: Biopharmaceutical Manufacturing, Global, Production Capacity by Company (%), 2011
Figure 4: Biopharmaceutical Manufacturing in India, China and South Korea, Geographical Distribution of Cell Culture Capacity (000’ liters), 2011-2017
Figure 5: Biopharmaceutical Manufacturing in India, China and South Korea, Volume Requirement for Different Biopharmaceuticals, (000’ liters), 2011-2017
Figure 6: Biopharmaceutical Manufacturing, Product Demand Distribution in Monoclonal Antibodies (%), Global, 2011
Figure 7: Biopharmaceutical Manufacturing, Biopharmaceutical Manufacturing Process, Global, 2012
Figure 8: Biopharmaceutical Manufacturing, Contract Manufacturing and the Drug Discovery and Research Market, Global, 2007-2016
Figure 9: Biopharmaceutical Manufacturing, Percentage of Outsourcing Non-Core Activities, Global, 2011
Figure 10: Biopharmaceutical Manufacturing in India, China and South Korea, Factors Driving Growth of CRAMS, 2012
Figure 11: Biopharmaceutical Manufacturing in India, China and South Korea, Roche Case Study, 2011
Figure 12: Biopharmaceutical Manufacturing, Formula for Standard Operating Cost, Global, 2011
Figure 13: Biopharmaceutical Manufacturing, Best and Most Likely Case Estimate Scenarios, Labor Cost ($’000), India and China, 2011-2046
Figure 14: Biopharmaceutical Manufacturing in India, China and South Korea, Timeframes in Months for Various Activities Involved in the Chemistry, Manufacturing and Control Tasks for Monoclonal Antibody Product Development, 2011
Figure 15: Biopharmaceutical Manufacturing in India, China and South Korea, Timeframes in Months for Various Activities Involved in the Chemistry, Manufacturing and Control Tasks for Monoclonal Antibody Product Development, 2011 (Continued)
Figure 16: Biopharmaceutical Manufacturing in India, China and South Korea, Comparative Analysis of Used Equipment Versus New Equipment, Global, 2011
Figure 17: Biopharmaceutical Manufacturing, Pharmaceutical Deal Value ($bn) and Number of Deal, Global, 2005-2012
Figure 18: Biopharmaceutical Manufacturing, Market Shares of the Pharmaceutical Companies, Contract Manufacturers and Equity Players (%), Global, 2007-2011
Figure 19: Biopharmaceutical Manufacturing, Perfect Partner Relationship, Global, 2011
Figure 20: Biopharmaceutical Manufacturing in India, China and South Korea, Comparative Analysis with Reference to Government Initiatives, Investments and Skills, 2011
Figure 21: Biopharmaceutical Manufacturing in India, China and South Korea, Market for Vaccines in India ($m), 2011-2016
Figure 22: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical Market in India ($bn), 2008-2016
Figure 23: Biopharmaceutical Manufacturing in India, China and South Korea, Drivers and Barriers for Biopharmaceutical Manufacturing, India, 2011
Figure 24: Biopharmaceutical Manufacturing in India, China and South Korea, Major Pharmaceutical Manufacturing Clusters in India, 2011
Figure 25: Biopharmaceutical Manufacturing in India, China and South Korea, Regulatory Framework for Recombinant Drugs, India, 2011
Figure 26: Biopharmaceutical Manufacturing in India, China and South Korea, Biocon, Company Overview, 2011
Figure 27: Biopharmaceutical Manufacturing in India, China and South Korea, Serum Institute of India, Company Overview, 2011
Figure 28: Biopharmaceutical Manufacturing in India, China and South Korea, Panacea Biotec, Company Overview, 2011
Figure 29: Biopharmaceutical Manufacturing in India, China and South Korea, Dr. Reddy’s, Company Overview, 2011
Figure 30: Biopharmaceutical Manufacturing in India, China and South Korea, Cipla, Company Overview, 2011
Figure 31: Biopharmaceutical Manufacturing in India, China and South Korea, Lupin, Company Overview, 2011
Figure 32: Biopharmaceutical Manufacturing in India, China and South Korea, Pharmaceutical and Biopharmaceutical Market ($bn),China, 2011-2015
Figure 33: Biopharmaceutical Manufacturing in India, China and South Korea, Contract Manufacturing Market, China ($bn), 2011-2015
Figure 34: Biopharmaceutical Manufacturing in India, China and South Korea, Hualan Biological Engineering Company Overview, 2011
Figure 35: Biopharmaceutical Manufacturing in India, China and South Korea, Shanghai Kehua Biological Engineering Co. Ltd, Company Overview, 2011
Figure 36: Biopharmaceutical Manufacturing in India, China and South Korea, Beijing Tiantan Biological Products Co. Ltd, Company Overview, 2011
Figure 37: Biopharmaceutical Manufacturing in India, China and South Korea, Beijing SL Pharmaceutical Co., Ltd, Company Overview, 2011
Figure 38: Biopharmaceutical Manufacturing in India, China and South Korea, Shanghai RAAS Blood Products Co., Ltd, Company Overview, 2011
Figure 39: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical Market, South Korea ($bn), 2011-2016
Figure 40: Biopharmaceutical Manufacturing in India, China and South Korea, Evolution of Biopharmaceuticals, South Korea
Figure 41: Biopharmaceutical Manufacturing in India, China and South Korea, Celltrion, Company Overview, 2011
Figure 42: Biopharmaceutical Manufacturing in India, China and South Korea, LG Life Sciences, Company Overview, 2011
Figure 43: Biopharmaceutical Manufacturing in India, China and South Korea, Hanwha Chemical, Company Overview, 2011
Figure 44: Biopharmaceutical Manufacturing in India, China and South Korea, ISU Abxis, Company Overview, 2011
Figure 45: Biopharmaceutical Manufacturing in India, China and South Korea, Green Cross, Company Overview, 2011